tion
technolog
red
blood
cell
unit
whole
blood
donat
suggest
univers
applic
technolog
foster
paradigm
shift
manufactur
safe
blood
neither
artifici
oxygen
carrier
hemostat
agent
potenti
replac
manufactur
red
blood
cell
rbc
unit
platelet
concentr
donat
healthi
volunt
natur
sourc
inher
bear
risk
transmit
bloodborn
pathogen
although
stringent
donor
select
criteria
sensit
specif
blood
screen
test
substanti
increas
safeti
margin
blood
recipi
particular
success
introduct
nucleic
acid
amplif
test
nat
hiv
hbv
hcv
led
significantli
safer
blood
product
result
residu
risk
million
million
current
risk
bacteri
contamin
especi
platelet
concentr
transfusionrel
bacteri
sepsi
time
fatal
relev
infecti
complic
vast
major
patient
receiv
platelet
concentr
suffer
hematolog
malign
vulner
bacteria
lead
higher
rate
infecti
complic
associ
comorbid
prolong
hospit
stay
furthermor
transfusionassoci
bacteri
infect
may
underestim
due
fact
fever
common
complic
patient
use
antibiot
mask
symptom
transfus
reaction
capac
inactiv
po
pathogen
inactiv
blood
safeti
dengu
viru
chikungunya
viru
west
nile
viru
bacteria
protozoa
platelet
concentr
red
blood
cell
random
clinic
trial
hemovigil
nowaday
patient
receiv
blood
compon
expos
much
less
transfusiontransmit
infecti
diseas
three
decad
among
other
hiv
identifi
caus
agent
acquir
immunodefici
syndrom
transmiss
blood
coagul
factor
becam
evid
sinc
time
implement
measur
risk
prevent
safeti
precaut
social
polit
accept
current
emerg
pathogen
like
arbovirus
wellknown
bacteri
contamin
platelet
concentr
still
remain
major
concern
blood
safeti
import
clinic
consequ
rare
fatal
outcom
blood
recipi
contrast
wellestablish
pathogen
inactiv
strategi
fresh
frozen
plasma
use
solventdeterg
procedur
methylen
blue
visibl
light
benchtobedsid
translat
novel
pathogen
inactiv
technolog
cellcontain
blood
compon
platelet
red
blood
cell
still
underway
review
summar
pharmacologicaltoxicolog
assess
inactiv
efficaci
virus
bacteria
protozoa
current
avail
pathogen
inactiv
technolog
highlight
impact
result
obtain
sever
random
clinic
trial
hemovigil
data
european
countri
pathogen
inactiv
technolog
routin
use
singledonor
plasma
platelet
invent
adapt
pathogen
inactivatenti
contamin
bacteria
platelet
concentr
focu
articl
briefli
summar
subsect
inactiv
efficaci
current
pathogen
inactiv
technolog
addit
still
imposs
know
reliabl
predict
emerg
pathogen
threaten
safeti
blood
suppli
end
question
deal
appear
new
reemerg
pathogen
novel
technolog
invent
use
improv
blood
safeti
patient
european
union
elsewher
focu
ongo
discuss
social
point
view
desir
pursu
zerorisk
strategi
complet
prevent
transfusiontransmit
infect
well
known
specif
industri
sector
aircraft
technolog
nuclear
energi
implement
program
continu
qualiti
improv
risk
manag
essenti
approxim
goal
zerorisk
impact
unfortun
event
probabl
occurr
import
determin
factor
quantit
risk
assess
root
caus
analysi
transfusiontransmit
infect
effect
stage
hazard
prevent
elimin
hazard
pathogen
follow
strategi
mitig
risk
transmiss
eg
donor
deferr
pathogen
screen
pathogen
inactiv
review
focus
exemplifi
descript
epidemiolog
surveil
arboviru
infect
potenti
risk
blood
safeti
due
fact
asymptomat
virem
phase
knowledg
nat
assay
dengu
viru
denv
chikungunya
viru
chikv
westnil
viru
wnv
develop
partli
commerci
avail
context
invent
precommerci
develop
introduct
market
univers
pathogen
inactiv
technolog
pit
attract
step
toward
manufactur
steril
cellular
blood
compon
human
sourc
global
matter
cours
cellfre
solut
human
origin
albumin
immunoglobulin
coagul
factor
decad
pit
impli
proactiv
gener
approach
multipl
new
emerg
pathogen
perpetu
challeng
safeti
blood
suppli
becom
seriou
altern
repetit
implement
new
screen
test
eg
nat
therefor
innov
design
paradigm
shift
transfus
medicin
review
summar
upcom
pit
focu
cellular
blood
compon
platelet
rbc
highlight
current
progress
clinic
evalu
pathogen
emerg
either
de
novo
mutat
cross
speci
barrier
human
be
hiv
excel
exampl
lifethreaten
emerg
infecti
diseas
aid
first
diagnos
patient
pneumocysti
carinii
pneumonia
kaposi
sarcoma
alert
us
center
diseas
control
prevent
care
monitor
outbreak
new
diseas
mainli
affect
haitian
homosexu
hemophiliac
iv
drug
user
two
independ
research
group
robert
gallo
luc
montagni
publish
discoveri
novel
retroviru
caus
agent
scienc
wide
accept
hiv
origin
simian
immunodefici
viru
siv
infect
chimpanze
cross
animalhuman
barrier
mutat
hiv
spread
throughout
societi
highrisk
transmiss
channel
www
wikipediaorg
hiv
antibodi
detect
assay
commerci
avail
sinc
implement
blood
donor
screen
worldwid
prevent
transmiss
via
blood
coagul
factor
human
origin
lesson
learn
aid
led
wellestablish
concept
emerg
infect
relev
transfus
medicin
especi
relev
case
donor
potenti
infect
eg
virem
yet
symptom
transmiss
via
blood
transfus
probabl
proven
true
denv
chikv
transmit
via
mosquito
aed
aegypti
aed
albopictu
dengu
fever
infecti
tropic
diseas
commonli
selflimit
accompani
flulik
symptom
skin
rash
similar
measl
howev
rare
instanc
lifethreaten
dengu
hemorrhag
fever
develop
sinc
incid
denv
increas
dramat
due
urban
popul
growth
global
warm
million
individu
infect
annual
endem
countri
worldwid
countri
donor
deferr
appropri
measur
prevent
neither
approv
vaccin
specif
antivir
drug
current
avail
addit
elimin
mosquito
habitat
protect
mosquito
bite
wear
cloth
prevent
measur
sever
outbreak
nonendem
region
texa
florida
australia
also
franc
n
croatia
n
madeira
n
individu
never
left
home
countri
suffer
dengu
fever
furthermor
evid
one
vector
aed
albopictu
habitat
nondengu
virusinfect
germani
austria
switzerland
stow
away
itali
commerci
transport
denv
transmit
blood
transfus
solid
organ
transplant
rare
case
two
small
outbreak
transfusiontransmit
denv
hong
kong
singapor
publish
incid
denv
rna
healthi
blood
donor
assess
eg
puerto
rico
brazil
rate
asymptomat
denv
rnaposit
individu
estim
denv
epidem
outbreak
serv
addit
sourc
viru
dissemin
commun
germani
robertkochinstitut
detect
individu
dengu
fever
acquir
infect
travel
wwwrkide
larg
chikv
outbreak
taken
place
indian
ocean
india
southeast
asia
europ
chikv
caus
febril
ill
pain
sometim
longlast
year
arthralgia
particular
outbreak
la
reunion
affect
nearli
one
third
island
popul
human
case
death
collaps
region
blood
suppli
prevent
import
blood
compon
franc
urgent
implement
intercept
tm
pit
suffici
platelet
support
air
travel
ship
around
world
contribut
spread
chikv
recogn
caus
unexpect
chikv
outbreak
northern
itali
summer
outbreak
limit
patient
caus
infecti
travel
current
widespread
humanmosquitohuman
transmiss
cycl
vector
aed
albopictu
deem
unlik
europ
usa
viru
persist
cold
temperatur
mosquito
activ
decreas
parallel
viru
wellestablish
socioeconom
framework
place
intern
surveil
network
emerg
wnv
usa
trace
back
first
case
wnv
import
new
york
human
case
death
wnv
mosquitoborn
rna
viru
whose
primari
host
bird
epidem
observ
individu
affect
mortal
rate
approxim
n
due
sever
meningoenceph
transfusiontransmit
wnv
infect
detect
asymptomat
contrast
case
fatal
leadership
us
food
drug
administr
fda
research
organ
blood
donat
agenc
screen
test
manufactur
build
task
forc
develop
industri
scalingup
valid
wnv
nucleic
acid
amplif
technolog
summer
wnv
nat
test
system
minipool
design
implement
allow
screen
viral
rna
specimen
pool
donor
six
breakthrough
wnv
infect
led
novel
concept
provid
season
switch
sensit
individu
donat
nat
platform
occasion
wnv
infect
miss
due
viral
titer
lower
limit
detect
recent
report
morbid
mortal
weekli
report
august
center
diseas
control
prevent
wwwcdcgov
immunocompromis
patient
nonhodgkin
lymphoma
die
diffus
wnv
enceph
wnv
epidem
occur
everi
year
usa
one
sever
outbreak
took
place
neuroinvas
case
virem
donor
compar
wnv
outbreak
patient
neuroinvas
form
virem
donor
wnvnat
test
first
time
phylogeograph
model
creat
base
wnv
genom
sequenc
sampl
organ
reconstruct
spatiotempor
diffus
wnv
north
america
specul
bird
movement
may
respons
rapid
longdist
movement
kmyear
viru
european
union
neighbor
countri
addit
other
border
mediterranean
sea
eastern
europ
wwwecdceuropeeu
increas
number
autochthon
wnv
infect
document
european
network
arthropod
vector
surveil
human
public
health
vbornet
support
european
center
diseas
control
ecdc
take
measur
prevent
control
local
outbreak
panel
expert
field
entomolog
scientif
studi
insect
transfus
medicin
exampl
third
consecut
year
human
case
wnv
infect
identifi
northeastern
itali
trend
toward
wider
geograph
area
therefor
prevent
strategi
current
discuss
european
union
paulehrlichinstitut
germani
minim
risk
wnv
transmiss
via
blood
solid
organ
tempor
deferr
atrisk
donor
implement
sensit
nat
screen
test
wwwpeid
emerg
novel
pathogen
rather
unpredict
although
mathemat
model
suggest
everi
year
new
transfusiontransmiss
infecti
agent
emerg
uptod
epidemiolog
data
prerequisit
proper
risk
assess
especi
travel
blood
donor
return
endem
area
europ
control
epidem
utmost
import
kept
precautionari
surveil
nation
intern
bodi
sever
emerg
pathogen
like
transmiss
blood
transfus
blood
safeti
emerg
bloodborn
pathogen
major
public
health
concern
also
true
known
virus
genom
mutat
suscept
immun
escap
mechan
new
strain
bacteria
emerg
pathogen
parasit
spread
intern
travel
climat
chang
denv
plasmodium
falciparum
trypanosoma
cruzi
babesia
necroti
procedur
address
risk
assess
emerg
infecti
diseas
potenti
transmiss
blood
blood
product
recent
discuss
usa
base
strong
scientif
evid
polici
maker
care
consid
strategi
optim
risk
minim
prevent
collaps
nation
blood
suppli
underand
overestim
actual
risk
undesir
potenti
disastr
consequ
absenc
avail
blood
screen
test
deferr
blood
donor
like
best
altern
mitig
risk
dissemin
amplitud
howev
case
high
incid
strategi
impli
disadvantag
paralyz
least
tempor
blood
suppli
futur
univers
applic
technolog
robust
pathogen
inactiv
may
becom
accept
strategi
circumv
risk
technolog
also
potenti
replac
routin
gammairradi
bacteri
test
cmv
serolog
also
scrutin
use
valuabl
test
system
detect
viral
antigen
antibodi
nucleic
acid
histor
cellfre
blood
compon
human
plasma
pathogeninactiv
solventdeterg
sd
larg
plasma
pool
addit
methylen
blue
mb
singl
plasma
product
smallsiz
blood
establish
gener
pathogen
inactiv
result
reduc
factor
viii
activ
fibrinogen
content
surprisingli
result
obtain
random
clinic
trial
rct
compar
sd
plasma
mb
plasma
convent
ffp
publish
great
extent
mention
method
transfer
cellcontain
blood
compon
heavili
damag
platelet
erythrocyt
therefor
review
focu
novel
pit
becom
increasingli
avail
cellular
blood
compon
circumv
disastr
cell
kill
properti
notabl
intercept
tm
ceru
corpor
concord
ca
usa
mirasol
terumo
bct
lakewood
co
usa
theraflex
uv
macopharma
mouvaux
franc
repres
current
avail
technolog
platform
differ
stage
market
readi
contrast
sdmb
method
technolog
capac
treat
cellular
blood
compon
wherea
sdmb
treatment
plasma
possibl
intercept
technolog
base
supplement
synthet
psoralen
penetr
cellular
nuclear
membran
revers
bind
nucleic
acid
especi
pyrimidin
singleor
doublestrand
dna
rna
uva
light
exposur
nm
jcm
robustli
crosslink
nucleic
acid
oxygenindepend
manner
consequ
action
independ
potenti
cytotox
reactiv
oxygen
speci
ro
psoralen
natur
occur
substanc
found
lime
celeri
mode
action
care
investig
especi
high
frequenc
coval
crosslink
one
adduct
form
bp
inhibit
dna
rna
replic
well
transcript
repair
mechan
unbound
photoproduct
reduc
adsorpt
devic
integr
contain
set
platelet
uva
illumin
licens
time
enabl
readyforus
applic
routin
workflow
blood
bank
mirasol
technolog
depend
addit
vitamin
riboflavin
result
final
concentr
approxim
riboflavin
plu
broadspectrum
uv
light
nm
jml
correspond
jcm
riboflavin
photoproduct
found
natur
product
food
human
blood
albeit
much
lower
concentr
mirasoltr
platelet
product
riboflavin
serv
photosensit
electron
transfer
promot
oxid
nucleic
acid
especi
guanin
residu
without
bind
nucleic
acid
protein
lead
convers
riboflavin
lumichrom
photoproduct
riboflavininduc
damag
irrevers
replic
process
rnadna
repair
mechan
strongli
inhibit
frequenc
nucleic
acid
lesion
approxim
bp
howev
context
plasma
signific
role
mirasolgener
ro
shown
advers
affect
molecular
integr
avinlabil
coagul
factor
fviii
fibrinogen
enzym
like
direct
gener
superoxid
anion
ro
may
make
reevalu
gener
toxicolog
assess
necessari
theraflex
uv
technolog
platelet
reli
photodynam
agent
base
exclus
forc
narrowbandwidth
uvc
light
nm
jcm
irradi
time
min
induc
format
pyrimidin
dimer
ensur
optim
illumin
platelet
transfer
larg
illumin
bag
allow
homogen
penetr
thin
platelet
suspens
frequent
agit
addit
photoact
chemic
unnecessari
need
convent
pharmacokinet
toxicolog
assess
gener
toler
lack
immunogen
neoantigen
format
uvctreat
platelet
demonstr
dog
principl
theraflex
uv
technolog
also
applic
ffp
howev
higher
uvc
intens
need
circumv
quench
effect
protein
plasma
achiev
suffici
pathogen
reduct
rate
toxicolog
assess
discuss
pit
applic
platelet
summar
tabl
modifi
extens
test
use
vitro
vivo
assay
accord
standard
intern
confer
harmon
drug
develop
suggest
toxicolog
relat
safeti
concern
compound
absorpt
devic
integr
intercept
blood
system
patient
receiv
amotosalen
per
platelet
transfus
rat
mgkg
po
wherea
final
riboflavin
exposur
adult
much
higher
mg
per
transfus
howev
consider
mice
mgkg
iv
safeti
margin
calcul
consequ
mention
pit
platelet
pass
licens
procedur
eg
ce
mark
introduc
medic
devic
market
tabl
addit
wellknown
transfusiontransmit
virus
hiv
hbv
hcv
htlv
bacteria
consider
risk
transmit
pathogen
blood
donat
commonli
test
eg
bacteria
epsteinbarr
viru
ebv
parvo
unknown
pathogen
may
emerg
next
year
similar
appear
hiv
earli
must
note
patient
individu
burden
may
much
higher
estim
standard
risk
eg
million
usual
refer
singl
blood
transfus
may
suggest
primarili
caus
transfus
frequenc
entir
hospit
stay
treatment
period
especi
true
patient
chronic
especi
bacteri
contamin
platelet
concentr
eg
staphylococcu
epidermidi
bacillu
cereu
less
extent
rbc
eg
yersina
enterocolitica
serratia
marcescan
still
remain
signific
challeng
transfus
medicin
sever
impact
patient
outcom
includ
death
current
avail
pit
abl
prevent
major
transfusiontransmit
bacteri
infect
limit
respect
bacteri
spore
eg
bacillu
cereu
clostridium
tetani
produc
surviv
strategi
extrem
environment
condit
defin
dormant
nonreproduct
structur
highli
resist
head
desicc
freez
uv
irradi
well
chemic
enzymat
destruct
enter
veget
form
platelet
concentr
shown
spike
experi
furthermor
high
titer
bacteria
vitro
condit
alway
inactiv
suffici
eg
klebsiella
pneumonia
result
obtain
direct
comparison
mirasol
technolog
versu
bacteri
cultur
test
favor
pit
platelet
concentr
tabl
continu
next
page
tabl
pathogen
inactiv
efficaci
platelet
concentr
low
initi
contamin
level
cfu
per
product
nevertheless
studi
shown
parallel
limit
capac
bacteria
elimin
even
though
bacteri
contamin
occur
blood
donat
believ
low
bacteria
may
start
prolifer
rigor
entir
storag
period
initi
lag
phase
least
h
therefor
take
account
current
pit
appli
immedi
donat
within
day
exponenti
bacteri
outgrowth
pathogen
inactiv
take
place
unlik
limit
capac
could
neglect
transfus
practic
instanc
anim
model
viru
analog
human
viru
use
may
relev
draw
signific
conclus
recent
shown
porcin
parvo
use
realtim
pcr
inhibit
assay
could
demonstr
mirasol
reduc
intact
human
parvoviru
dna
plasma
log
compar
log
inhibit
porcin
tissu
cultur
infecti
dose
assay
logarithm
reduct
prefix
greater
indic
higher
infect
given
vitro
test
system
appli
author
would
like
point
viru
strain
viru
titrat
method
tissu
cultur
infecti
dose
calcul
platform
may
differ
among
competitor
involv
therefor
direct
sidetosid
comparison
studi
use
strain
viru
bacteri
speci
may
desir
ensur
high
degre
compar
reproduc
recent
isbt
work
parti
transfusiontransmit
infecti
diseas
publish
proof
principl
experi
valid
qualiti
stabil
suitabl
four
pei
bacteri
refer
staphylococcu
epidermidi
streptococcu
pyogen
klebsiella
pneumonia
escherichia
coli
platelet
concentr
lowtit
spike
experi
perform
laboratori
around
world
aim
intern
studi
success
fulfil
author
knowledg
uvcbas
theraflex
technolog
today
first
pit
use
refer
bacteria
panel
gener
inactiv
data
case
bacteria
spike
experi
high
titer
one
awar
robust
pathogen
kill
vitro
may
affect
problem
endotoxininduc
septic
shock
patient
practic
point
view
detect
steril
appli
pit
blood
compon
reason
bacteri
contamin
simul
scenario
con
tamin
donat
clinic
relev
pathogen
inactiv
profil
increasingli
complet
intercept
mirasol
wellknown
gap
hav
howev
especi
theraflex
uv
still
data
miss
transfusionassoci
virus
found
rel
resist
uvc
light
exposur
primarili
true
hiv
pit
rbc
whole
blood
current
develop
busi
success
patient
individu
advantag
regard
blood
safeti
mainli
depend
likelihood
receiv
pittreat
blood
compon
perman
pharmaceut
potenc
pathogeninactiv
platelet
princip
investig
radiolabel
studi
involv
retransfus
autolog
platelet
initi
collect
volunt
donor
storag
data
correct
radiolabel
effici
preinject
elut
minim
fda
requir
fresh
platelet
mean
recoveri
rate
life
span
day
fda
requir
demand
platelet
recoveri
day
least
correspond
initi
concentr
platelet
fresh
condit
platelet
surviv
correspond
day
compar
fresh
refer
platelet
produc
parallel
contrast
rbc
surviv
blood
circul
well
known
transfus
platelet
fill
spleen
pool
mean
recoveri
vs
lifespan
vs
day
publish
intercepttr
compar
nonirradi
refer
platelet
suspend
pasiii
furthermor
aubuchon
et
al
summar
result
obtain
mirasoltr
platelet
mean
proport
vs
recoveri
vs
day
lifespan
recent
first
result
n
phase
studi
theraflex
uv
technolog
publish
demonstr
signific
decreas
platelet
recoveri
surviv
rate
vs
vs
day
compar
pit
furthermor
thiel
et
al
present
preliminari
data
transfus
uvctreat
autolog
platelet
healthi
volunt
met
safeti
toler
criteria
upon
critic
review
data
pathogeninactiv
platelet
fulfil
minim
fda
criteria
vivo
qualiti
independ
technolog
appli
howev
raw
data
consist
indic
slight
signific
alter
vivo
qualiti
test
refer
group
studi
vivo
phenomenon
may
line
vitro
paramet
assess
function
integr
platelet
detect
higher
metabol
state
sign
activ
depend
ce
approv
mark
enabl
free
movement
good
eu
member
state
complet
phase
iii
rct
readi
market
introduct
vari
mention
pit
tabl
medic
devic
higher
risk
profil
classifi
higher
categori
intercept
devic
ce
mark
class
iii
product
amotosalen
requir
critic
review
clinic
data
eg
inactiv
efficaci
storag
notifi
bodi
demonstr
complianc
medic
devic
direct
approv
respect
nation
author
mirasol
devic
ce
mark
class
iib
product
riboflavin
need
principl
selfcertif
manufactur
author
knowledg
toxicolog
profil
inactiv
efficaci
clinic
data
mirasol
technolog
also
review
notifi
bodi
prior
approv
import
data
relev
clinic
trial
alreadi
publish
peerreview
journal
summar
tabl
intercepttr
platelet
result
obtain
sever
clinic
trial
enrol
patient
alreadi
publish
demonstr
strong
evid
gener
therapeut
efficaci
safeti
five
relev
phase
iii
studi
summar
detail
tabl
eurosprit
sprint
janetzko
et
al
kerkhoff
et
al
lozano
et
al
supplement
pilot
studi
phase
iii
studi
also
publish
list
tabl
due
limit
studi
design
perform
statu
sever
previous
discuss
issu
rather
controversi
especi
clinic
impact
lower
cicci
valu
correct
bleed
assess
accord
common
terminolog
criteria
advers
event
ctcae
classif
result
obtain
rct
publish
kerkhoff
et
al
hovon
studi
especi
contribut
confus
lack
blind
evalu
bleed
complic
import
critic
comment
observ
grade
bleed
hematolog
patient
transfus
prophylact
sharp
contrast
previou
recent
publish
data
approxim
make
hard
consid
result
especi
bleed
rct
must
taken
account
author
report
signific
increas
bleed
first
platelet
transfus
intercept
vs
plasma
p
grade
bleed
vs
p
interestingli
author
recent
publish
data
use
rigor
observ
adjud
method
assess
bleed
accur
consist
addit
one
group
develop
new
bleed
sever
measur
scale
assess
bleed
patient
chemotherapyinduc
thrombocytopenia
higher
level
valid
impact
revis
metaanalysi
includ
rct
lozano
et
al
exclud
singl
rct
use
mirasol
technolog
remain
question
data
publish
kerkhoff
still
part
analysi
howev
author
discuss
risk
bleed
complic
longer
increas
wherea
assess
risk
clinic
signific
bleed
complic
uncertain
strongli
depend
integr
exclus
singl
rct
line
addit
metaanalysi
exclud
hovon
studi
find
signific
differ
bleed
risk
reanalysi
sprint
data
confirm
equival
prevent
bleed
grade
number
transfus
pc
rbc
unit
addit
hemostat
effect
sprint
data
evalu
assess
advers
event
profil
acut
transfus
reaction
within
h
significantli
lower
intercept
studi
arm
compar
refer
platelet
suspend
plasma
vs
current
increas
evid
suggest
clinic
noninferior
intercepttr
platelet
compar
refer
platelet
postmarket
observ
studi
confirm
result
obtain
phase
iii
studi
data
larg
retrospect
studi
also
support
noninferior
assess
primarili
rct
demonstr
subsequ
stabl
consumpt
platelet
concentr
compar
patient
cohort
annual
util
hospit
intercept
implement
furthermor
signific
increas
rbc
transfus
recipi
transfus
pathogeninactiv
platelet
ossela
et
al
survey
advers
event
associ
routin
transfus
intercepttr
platelet
concentr
implement
multicent
activ
hemovigil
program
belgium
franc
spain
transfus
first
period
transfus
second
postmarket
surveil
studi
major
patient
suffer
either
hematolog
malign
chemotherapi
stem
cell
transplant
underw
cardiovascular
surgeri
solid
organ
transplant
children
pregnant
women
includ
receiv
pathogeninactiv
platelet
routin
workflow
latter
period
author
report
overal
infrequ
rate
acut
transfus
reaction
mainli
mild
sever
advers
event
consid
sever
without
causal
link
pit
furthermor
cazenav
et
al
summar
data
etabliss
francai
du
sang
alsac
implement
compar
clinic
safeti
toler
intercepttr
pc
approxim
recipi
refer
platelet
concentr
suspend
plasma
pasiii
author
state
signific
reduct
acut
transfus
reaction
evid
increas
rbc
consumpt
patient
receiv
intercepttr
pc
particip
center
pit
use
replac
gammairradi
anticmv
serolog
data
volum
level
evid
therapeut
efficaci
safeti
mirasol
pathogen
inactiv
technolog
less
pronounc
singl
multicent
openlabel
rct
noninferior
design
publish
etabliss
francai
du
sang
compar
mirasoltr
platelet
concentr
convent
product
either
apheresi
buffi
coatderiv
suspend
plasma
hematolog
patient
thrombocytopenia
base
result
trap
trial
noninferior
margin
equival
mean
correct
count
increment
hour
posttransfus
differ
defin
statist
power
consid
suffici
six
center
enrol
total
patient
four
patient
studi
arm
receiv
transfus
exclud
intentiontotreat
analysi
total
transfus
given
test
group
refer
group
frequenc
offprotocol
transfus
respect
primari
endpoint
studi
first
transfus
within
treatment
period
rct
fail
show
hypothes
noninferior
test
versu
refer
result
mean
decreas
correspond
approxim
secondari
outcom
show
compar
trend
mean
differ
differ
rate
bleed
reach
signific
vs
p
frequenc
grade
bleed
low
n
test
vs
n
refer
p
evalu
clinic
safeti
profil
term
bleed
complic
need
suffici
power
studi
design
even
author
conclud
clinic
studi
requir
determin
whether
drop
correl
increas
risk
bleed
far
smallsiz
observ
platelet
studi
perform
still
ongo
spain
luxembourg
lithuania
serbia
among
other
antic
et
al
shown
statist
signific
differ
test
control
group
correspond
valu
yanez
et
al
publish
base
transfus
patient
coen
et
al
also
shown
compar
valu
calcul
total
transfus
patient
although
author
state
advers
event
report
valid
inform
insuffici
due
small
patient
size
furthermor
similar
hemostat
function
mirasoltr
platelet
suggest
use
thrombelastographi
vivo
surrog
system
singl
observ
supersed
need
implement
activ
hemovigil
program
mirasoltr
platelet
concentr
routin
use
foster
rct
itali
one
addit
multicent
rct
calcul
size
patient
ipta
initi
use
mirasoltr
pc
suspend
pa
address
concern
clinic
relev
bleed
furthermor
prepar
studi
consortium
netherland
norway
canada
ongo
recruit
patient
receiv
mirasoltr
platelet
concentr
suspend
plasma
clinic
studi
complet
person
commun
ray
goodrich
plasma
platelet
concentr
deriv
pool
buffi
coat
collect
singledonor
apheresi
pathogeninactiv
use
intercept
mirasol
receiv
market
author
approv
european
noneuropean
nation
bodi
theraflex
uv
technolog
pit
appli
rbc
unit
whole
blood
see
still
earli
phase
clinic
evalu
clinic
experi
avail
million
postmarket
transfus
use
intercepttr
plasma
ca
platelet
ca
countri
person
commun
larri
corash
hemovigil
data
collect
review
systemat
mention
clinic
data
also
includ
experi
neonat
pediatr
patient
addit
nation
hemovigil
data
also
avail
franc
sinc
switzerland
sinc
data
avail
germani
although
paulehrlichinstitut
releas
first
manufactur
author
univers
hospit
luebeck
case
mirasol
compani
announc
mirasoltr
blood
compon
ca
plasma
ca
platelet
appli
particip
transfus
center
frequent
routin
use
without
sever
advers
event
obvious
increas
rate
advers
event
person
commun
ray
goodrich
howev
systemat
collect
hemovigil
data
post
market
author
yet
publish
none
pit
current
approv
fda
us
market
howev
ceru
corpor
announc
submiss
premarket
approv
applic
intercept
platelet
first
half
taken
togeth
inher
variabl
convent
platelet
concentr
independ
type
pit
use
must
note
wellaccept
decad
reason
explain
term
platelet
content
biolog
sourc
eg
volunt
donor
differ
platelet
concentr
peripher
blood
term
clinic
efficaci
either
natur
age
platelet
storag
non
aboident
use
eg
trap
trial
report
slichter
et
al
larg
random
multicent
trial
prophylact
platelet
dose
studi
plado
prophylact
platelet
transfus
patient
platelet
dose
correl
cci
transfus
result
higher
transfus
frequenc
necessarili
higher
incid
bleed
mind
must
ask
extent
lower
efficaci
bear
mind
noninferior
margin
becom
accept
higher
safeti
profil
result
use
pit
rather
call
efficaci
safeti
pittreat
platelet
question
aim
aspect
accept
regard
convent
platelet
product
past
eg
impair
storag
abo
nonident
use
furthermor
recent
publish
studi
wandt
et
al
invit
rethink
prophylact
platelet
transfus
strategi
patient
risk
increas
bleed
complic
eg
autolog
stem
cell
transplant
increas
major
hemorrhag
could
observ
patient
platelet
transfus
therapeut
howev
qualityoflif
aspect
remain
question
patient
physician
serious
affect
routin
monitor
bleed
becam
awar
perman
latent
danger
like
sword
damocl
pit
appli
platelet
transfer
whole
blood
rbc
unit
optic
dens
blood
compon
need
high
dose
uv
light
therefor
ceru
develop
novel
platform
technolog
gener
base
addit
chemic
compound
mmoll
glutathion
gsh
mmoll
quencher
target
crosslink
nucleic
acid
via
bisalkyl
group
prevent
replic
reaction
nonreact
neg
charg
breakdown
product
form
rapidli
degrad
minim
affin
nucleophil
especi
protein
glutathion
ad
distribut
extracellular
compart
plasma
quench
extracellular
reaction
wherea
act
pathogen
inactiv
intracellular
compart
treatment
solut
breakdown
product
remov
centrifug
prior
final
storag
approv
solut
gener
phase
iii
rct
chronic
anemia
patient
two
multitransfus
particip
develop
lowtit
antibodi
acridin
moieti
rbc
surfac
led
posit
crossmatch
reaction
vitro
without
cue
regard
clinic
impact
acut
hemolyt
transfus
reaction
nevertheless
phase
iii
studi
parallel
studi
cardiovascular
surgeri
patient
halt
prematur
ceru
develop
gener
technolog
minim
acridin
moieti
rbc
surfac
increas
concentr
protect
glutathion
pathogen
inactiv
process
subsequ
inactiv
efficaci
bacteria
virus
protozoa
gener
approach
well
pharmacokinet
toxicolog
assess
princip
transfer
gener
tabl
person
commun
larri
corash
crossrefer
accept
fda
ident
substanc
use
new
phase
studi
conduct
total
healthi
volunt
receiv
autolog
rbc
transfus
use
dual
radiolabel
approach
use
cr
tc
gener
induc
antibodi
format
recoveri
day
excel
mean
demonstr
equival
untreat
rbc
refer
arm
recoveri
median
lifespan
significantli
reduc
vs
day
wherea
vitro
evalu
day
storag
shown
equival
hemolysi
extracellular
potassium
mean
corpuscular
hemoglobin
concentr
mean
corpuscular
volum
margin
loss
hemoglobin
treatment
pit
rbc
readi
run
renew
middles
n
patient
phase
iii
clinic
studi
european
union
patient
enrol
began
elect
cardiac
surgeri
patient
acut
blood
loss
thalassemia
patient
chronic
transfus
demand
person
commun
larri
corash
clinic
studi
focu
hemoglobin
content
latter
case
potenti
immunogen
repeat
exposur
furthermor
compani
announc
ceru
whole
blood
initi
support
swiss
red
cross
humanitarian
fund
pursu
applic
technolog
whole
blood
develop
countri
humanitarian
effort
riboflavinbas
pit
success
evalu
platelet
plasma
develop
whole
blood
achiev
ultim
goal
singl
pit
platform
abl
inactiv
three
blood
compon
simultan
understand
toxicolog
assess
data
concern
neoantigen
protein
bind
behavior
could
extrapol
whole
blood
system
well
shown
baboon
studi
model
riboflavin
induc
chemic
modif
surfac
rbc
possess
immunogen
moieti
safeti
efficaci
assess
larg
anim
model
diffus
nonsurg
bleed
pig
model
drugrel
terminolog
phase
iiii
studi
avoid
fact
mirasol
system
rather
medic
devic
drug
person
commun
ray
goodrich
howev
context
gener
ro
classif
reconsid
feasibl
data
rbc
day
storag
separ
whole
blood
donat
n
treat
riboflavin
increas
dose
uv
light
energi
case
jml
usa
shown
high
variabl
ca
rbc
recoveri
rbc
halflif
day
day
rang
day
five
subject
met
fda
criteria
treatment
success
defin
autolog
recoveri
radiolabel
rbc
h
lower
limit
ci
recoveri
howev
rang
gammairradi
rbc
unit
rate
hemolysi
day
day
osmot
fragil
increas
depend
uv
light
dose
chosen
recent
report
compani
current
configur
base
exposur
higher
dose
uv
light
jml
compens
suffici
uv
light
absorpt
hemoglobin
choos
compar
uv
energi
dose
qualiti
separ
blood
compon
eg
rate
hemolysi
maintain
standard
storag
period
still
accept
inactiv
efficaci
broad
spectrum
pathogen
summar
tabl
howev
data
person
commun
yet
confirm
origin
articl
peerreview
journal
riboflavin
uv
treatment
gammairradi
equal
effect
prevent
transfusionassoci
graftversushostdiseas
result
vitro
log
reduct
viabl
cell
subsequ
confirm
immunodefici
murin
recipi
nodscid
null
compani
start
improv
ii
rct
compar
phase
ii
studi
radiolabel
rbc
usa
obvious
valid
impact
process
optim
uv
light
dose
fixat
jml
mirasol
treatment
rbc
qualiti
loss
inactiv
efficaci
futur
one
focus
potenti
clinic
applic
mirasoltr
whole
blood
militari
scenario
allow
immedi
substitut
safe
rbc
platelet
plasma
case
lifethreaten
trauma
traumainduc
coagulopathi
impact
interestingli
addit
rct
take
place
ghana
patient
evalu
prevent
whole
bloodassoci
malaria
transmiss
mirasolbas
inactiv
whole
blood
donat
person
commun
ray
goodrich
ps
receiv
honorarium
travel
reimburs
speaker
chair
ceru
europ
bv
